Table 3

Series of SMZL patients treated with splenectomy

ReferenceYearNResponseOSDeaths due to surgery
ORR (%)Duration
Mulligan et al6819912095Median DOR 4 yNR1
Troussard et al5919962875NR71% at 5 y1
Chacon et al6120026093.3Median FFS 40 mo65% at 5 yNR
Thieblemont et al1200248100PFS 48% at 5 yNRNR
Parry-Jones et al60200333NRNRLSS 95% at 10 yNR
Iannitto et al6920042191Median DOR 4 yNRNR
Tsimberidou et al7020061060FFS 80% at 3 y89% at 3 y0
Olszewski et al712012652NRNR67.8% at 5 yNR
Kalpadakis et al7320132785PFS 58% at 5 y77% at 5 y1
Lenglet et al7201410097PFS 61% at 5 y84% at 5 y0
Xing et al62201552§NRFFS 39% at 10 y61% at 10 y0
Pata et al8920154190PFS 35% at 5 y75% at 5 y0
  • DOR, duration of response; FFS, failure-free survival; LSS, lymphoma-specific survival; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

  • Splenectomy alone in 29 patients.

  • Splenectomy alone in 25 patients.

  • Survival of entire series of 1251 patients with no impact of splenectomy on OS.

  • § Splenectomy alone in 42 patients.